Pictured at the New York stock exchange on Monday 14th March, 2011, on the left is Pat O’Flynn (CEO Solvotrin Therapeutics) and on the right is Dr. Mark Ledwidge (VP Development and Strategy Solvotrin Therapeutics).
Pat O’Flynn addressed a group of more than 300 executives from America’s biggest companies, along with venture capitalists, leading Irish businesses and Irish government representatives at the New York Stock Exchange yesterday.
Solvotrin Therapeutics announced an exciting update on the development of the lead antidyslipidaemic (anti-cholesterol) product in the Solvotrin portfolio of patent- protected bioactivated medicines.
Speaking from the New York Stock Exchange, Pat O’Flynn, Solvotrin Therapeutics CEO, announced that the niacin prodrug (ST0702) has performed exceptionally well in preclinical trials, demonstrating significant efficacy and tolerability advantages over currently available products.
The company has been creating a stir in the investment community and the Life Sciences industry in the USA.
SOLVOTRIN TEAM PROMOTING IRELAND INC. IN NEW YORK The Solvotrin Board of Directors including Pat O’Flynn, Dr. John Gilmore, Dr. Mark Ledwidge and Mr. John O’Flynn were active participants at the Ireland Day event at the NYSE.
Also included in the panel discussions were Digicel’s Denis O’Brien, Liam Casey of PCH, John Bruton, Chairman of the IFSC, New York Mayor Bloomberg, Terry Maguire, Polaris Venture Capital and Dave Shanahan, IDA Ireland.